<DOC>
	<DOCNO>NCT01686880</DOCNO>
	<brief_summary>The purpose study assess safety transarterial radioembolization prior surgical resection radiofrequency cirrhotic patient hepatocellular carcinoma</brief_summary>
	<brief_title>Y90 Radioembolization Prior Surgical Resection Radiofrequency Hepatocellular Carcinoma Cirrhotic Liver</brief_title>
	<detailed_description>The purpose study ass peri-operative morbidity mortality supraselective ablative transarterial radioembolization prior surgical resection radiofrequency cirrhotic patient HCC</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<criteria>Age ≥18 year . Cirrhotic liver demonstrate typical liver dysmorphy image and/or liver biopsy . HCC least one lesion measure 1 cm diameter single dynamic imaging technique ( CT MRI ) , show intense arterial uptake follow washout contrast venousdelayed phase , diagnose biopsy . Borderline resectable disease eligible surgical resection radiofrequency destruction . No extrahepatic dissemination . ECOG Performance status &lt; 2 . Women childbearing potential must agree use adequate contraception ( hormonal barrier method birth control , abstinence ) prior study entry duration study participation . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately . Signed write inform consent ( approved Independent Ethics Committee ) obtain prior study specific baseline procedure . Decompensated cirrhosis ( Child Pugh B , C ) . Extrahepatic tumour spread . Previous concomitant malignancy within five year basal cell carcinoma skin . Pregnancy , lactation refusal use adequate contraceptive measure ( hormonal barrier method birth control , abstinence ) . Preexisting hepatic disease ( liver abscess , hepatic sarcoidosis tuberculosis , sclerosing cholangitis , … ) . Previous transarterial radioembolization ( TARE ) . History allergic reaction attribute compound similar chemical biologic composition administer material . Bleeding diathesis , history cardiovascular ischemic disease cerebrovascular incident within last six month . Major surgery within four week . Uncontrolled concurrent illness include , limited ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . Uncontrolled Diabetes .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Hepatocellular Carcinoma</keyword>
	<keyword>Liver Cirrhosis</keyword>
	<keyword>radioembolization</keyword>
	<keyword>SIRT</keyword>
	<keyword>TARE</keyword>
	<keyword>Sirspheres</keyword>
	<keyword>neoadjuvant</keyword>
	<keyword>liver cancer</keyword>
</DOC>